ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Genentech gets $62 million in BARDA funding for flu, mustard agent treatments

by Lisa M. Jarvis
October 7, 2018 | APPEARED IN VOLUME 96, ISSUE 40

 

Genentech will receive $62 million from the U.S. Biomedical Advanced Research & Development Authority (BARDA) to help develop a flu treatment and a drug for mustard agent exposure. The bulk of the cash will be distributed over five years to support clinical studies of baloxavir marboxil, an antiviral for people who have been hospitalized because of seasonal or pandemic flu. Some $19 million will go to develop alteplase, a drug already approved for heart attacks and stroke that shows promise in treating lung damage after mustard agent inhalation.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment